ATE208374T1 - Beta-laktam und cepham verbindungen und ihre herstellung - Google Patents

Beta-laktam und cepham verbindungen und ihre herstellung

Info

Publication number
ATE208374T1
ATE208374T1 AT93903302T AT93903302T ATE208374T1 AT E208374 T1 ATE208374 T1 AT E208374T1 AT 93903302 T AT93903302 T AT 93903302T AT 93903302 T AT93903302 T AT 93903302T AT E208374 T1 ATE208374 T1 AT E208374T1
Authority
AT
Austria
Prior art keywords
lactam
beta
optionally substituted
production
compound
Prior art date
Application number
AT93903302T
Other languages
English (en)
Inventor
Shigeru Torii
Hideo Tanaka
Mitio Sasaoka
Takashi Shiroi
Yutaka Kameyama
Original Assignee
Otsuka Kagaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP03031092A external-priority patent/JP3227497B2/ja
Priority claimed from JP03031192A external-priority patent/JP3265381B2/ja
Application filed by Otsuka Kagaku Kk filed Critical Otsuka Kagaku Kk
Application granted granted Critical
Publication of ATE208374T1 publication Critical patent/ATE208374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
AT93903302T 1992-02-18 1993-02-03 Beta-laktam und cepham verbindungen und ihre herstellung ATE208374T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP03031092A JP3227497B2 (ja) 1992-02-18 1992-02-18 β−ラクタム化合物及びその製造法
JP03031192A JP3265381B2 (ja) 1992-02-18 1992-02-18 ２−置換メチル−３−セフェム化合物及びその製造法並びに２−エキソメチレンセフェム誘導体の製造法
PCT/JP1993/000131 WO1993016043A1 (en) 1992-02-18 1993-02-03 β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF

Publications (1)

Publication Number Publication Date
ATE208374T1 true ATE208374T1 (de) 2001-11-15

Family

ID=26368636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93903302T ATE208374T1 (de) 1992-02-18 1993-02-03 Beta-laktam und cepham verbindungen und ihre herstellung

Country Status (5)

Country Link
US (2) US5470972A (de)
EP (1) EP0592677B1 (de)
AT (1) ATE208374T1 (de)
DE (1) DE69331089T2 (de)
WO (1) WO1993016043A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP2796468A2 (de) 2001-01-05 2014-10-29 Pfizer Inc Antikörper für Insulinähnlichen Wachstumsfaktor-1-Rezeptor
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
IL164287A0 (en) * 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
ES2557769T3 (es) 2003-03-19 2016-01-28 Amgen Fremont Inc. Anticuerpos contra el antígeno del dominio de inmunoglobulina de células T y el dominio 1 de mucina (TIM-1) y usos de los mismos
SI2177537T1 (sl) * 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EP3312196B1 (de) 2005-03-23 2019-07-17 Genmab A/S Antikörper gegen cd38 zur behandlung von multiplem myelom
EP2384767B1 (de) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. OV064-bindende Antikörper und Verfahren zu deren Verwendung
KR101203328B1 (ko) 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
US8642330B2 (en) * 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
EA014025B1 (ru) * 2005-09-12 2010-08-30 Новиммун С.А. Композиции антитела против cd3
EP1957115B8 (de) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Verfahren zur behandlung von ovarial- und nierenkarzinom mit antikörpern gegen t-zell-immunglobulin-domänen- und mucin-domänen-1-(tim-1)-antigen
AU2006321593B2 (en) 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
CN101578297A (zh) * 2006-04-07 2009-11-11 美国政府健康及人类服务部 治疗肿瘤疾病的抗体组合物和方法
JP2010534719A (ja) * 2007-07-27 2010-11-11 ファイザー・リミテッド 沈殿化による抗体精製方法
CA2935651A1 (en) 2007-10-09 2009-04-16 Gladius Pharmaceuticals Corporation Broad spectrum beta-lactamase inhibitors
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
US8137671B2 (en) 2009-05-05 2012-03-20 Genentech, Inc. Anti-IL-17F antibodies
CA2774032C (en) 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
US9211302B2 (en) 2011-01-17 2015-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation of LRCH4 activity and therapeutic application thereof
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
CA2835603A1 (en) 2011-05-09 2012-11-15 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US9593165B2 (en) 2012-11-08 2017-03-14 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
WO2014123580A1 (en) 2013-02-06 2014-08-14 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
EP3441071A1 (de) 2013-03-12 2019-02-13 Gladius Pharmaceuticals Corporation Derivatisierte cephalosporine
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
JP6552412B2 (ja) 2013-09-05 2019-07-31 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
CA2967379A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
AU2017234163B2 (en) 2016-03-15 2023-01-19 Mersana Therapeutics, Inc. NaPi2b-targeted antibody-drug conjugates and methods of use thereof
WO2017221883A1 (ja) 2016-06-20 2017-12-28 武田薬品工業株式会社 抗体－薬物コンジュゲート
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
JP7410051B2 (ja) 2018-11-20 2024-01-09 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
IT201900008376A1 (it) 2019-06-07 2020-12-07 Univ Degli Studi Di Modena E Reggio Emilia Anticorpi ad attività antitumorale
EP4026560A4 (de) 2019-09-04 2023-10-25 Perseus Proteomics Inc. Therapeutisches mittel für polyzythämie
JP7622926B2 (ja) 2019-11-27 2025-01-28 株式会社ペルセウスプロテオミクス 癌性腹膜炎の治療薬
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
WO2021247908A1 (en) 2020-06-03 2021-12-09 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
JP7789304B2 (ja) 2020-07-31 2025-12-22 バイオ－テラ ソリュ－ションズ，エルティーディー． Ｃｄ４７抗体及びその応用
WO2022075439A1 (ja) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
CN117836003A (zh) 2021-08-26 2024-04-05 株式会社英仙蛋白质科学 Ros（活性氧类）产生增强剂
WO2023116911A1 (zh) 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
KR20250007549A (ko) 2022-04-19 2025-01-14 토카이 유니버시티 에듀케이셔널시스템 Nk 세포종양 치료제
EP4635983A1 (de) 2024-04-15 2025-10-22 Ymmunobio AG Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT342197B (de) * 1975-02-20 1978-03-28 Ciba Geigy Ag Neues verfahren zur herstellung von 3-cephemverbindungen
JPS5214789A (en) * 1975-07-22 1977-02-03 Shionogi & Co Ltd Process for preparing 3-substiuted cephem compounds by ring closure
JPS56118085A (en) * 1980-02-25 1981-09-16 Takeda Chem Ind Ltd 2-methylcephalosporin derivative and its preparation
EP0124081A3 (de) * 1983-05-02 1986-11-26 Merck & Co. Inc. Substituierte Cephalosporinsulfone mit Antientzündungs- und Antidegenerativwirkung, sie enthaltende Zusammensetzungen und Verfahren zur Herstellung
US5132301A (en) * 1983-05-02 1992-07-21 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
JPS60237061A (ja) * 1984-05-08 1985-11-25 Otsuka Chem Co Ltd アゼチジノン誘導体の製造法
NZ222399A (en) * 1986-11-12 1991-07-26 Merck & Co Inc Cephalosporin derivatives; pharmaceutical compositions and processes for preparation
GB8808701D0 (en) * 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
US5162521A (en) * 1991-06-06 1992-11-10 Bristol-Myers Squibb Company Processes for making cephems from allenylazetidinone derivatives

Also Published As

Publication number Publication date
EP0592677A4 (en) 1994-07-06
DE69331089T2 (de) 2002-07-18
EP0592677B1 (de) 2001-11-07
DE69331089D1 (de) 2001-12-13
WO1993016043A1 (en) 1993-08-19
US5470972A (en) 1995-11-28
EP0592677A1 (de) 1994-04-20
US5693792A (en) 1997-12-02

Similar Documents

Publication Publication Date Title
ATE208374T1 (de) Beta-laktam und cepham verbindungen und ihre herstellung
DE69020676D1 (de) Tricyclische Carbapenemverbindungen.
PT620225E (pt) Derivados de cefalosporina
ATE205199T1 (de) Quinolin- oder quinazolinderivate, deren herstellung und verwendung
ATE181066T1 (de) Zwischenverbindungen zur herstellung von thioalkylthio cephalosporinderivaten
DE69121259D1 (de) Beta-Lactam-Verbindungen und ihre Herstellung
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
KR950704333A (ko) 신규한 세펨 유도체(novel cephem derivatives)
ATE244248T1 (de) Herstellung von amino cephalosporansäurederivaten
EP1340756A4 (de) Neue beta-lactamverbindungen und verfahren zu deren herstellung
ATE200674T1 (de) Herstellung von beta-lactamverbindungen und zwischenprodukte
ATE109764T1 (de) Beta-lactamverbindungen und deren herstellung.
DE69331249D1 (de) Verfahren zur Herstellung von (1'R,3S,4R)4-Acylthioazetidinonen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee